Oral Ibrexafungerp Effective in Vulvovaginal Candidiasis Trial
Scynexis announced positive topline results from the phase 3 VANISH 303 trial of ibrexafungerp for the treatment of vulvovaginal candidiasis (VVC) in women.
Mycoses
Mycoses
Latest News
Higher Frequency of C albicans After Root Canals in Patients With Type 2 Diabetes
Patients with a long-term history of type 2 diabetes mellitus (T2DM) carried Candida albicans in their dental root canals more frequently when they have a primary endodontic infection.
Aspergillosis, ABPA-Related Hospitalizations in Cystic Fibrosis Confer Worse Outcomes
Nearly one-third of patients with cystic fibrosis-related hospitalizations have aspergillosis, which is associated with worse outcomes.
Oral Amphotericin B Formulation Gets Orphan Drug Status for Cryptococcosis
The Food and Drug Administration (FDA) has granted Orphan Drug designation to MAT2203 (Matinas BioPharma) for the treatment of cryptococcosis.
Novel Antifungal Gains Fast Track Designation for Seven Indications
The FDA has granted Fast Track designations to both the oral and intravenous formulations of fosmanogepix for 7 antifungal indications.
ATS Guideline Outlines Lab Tests for Diagnosis of Fungal Infections
Guideline addresses lab testing for diagnosis of fungal infections in pulmonary medicine, critical care
Key for Candida auris Prevention: Strict Adherence to Infection Control Measures
Multidrug-resistant Candida auris is an urgent antimicrobial resistance threat and the key method of prevention is strict adherence to infection control measures.
Invasive Aspergillosis and Mucromycosis Diagnosed With Real-Time PCR
A new real-time polymerase chain reaction assay shows promise in the noninvasive diagnosis of aspergillosis and mucormycosis.
T2Candida Diagnostic Test for ICU Patients at Risk for Invasive Candidiasis
The combination of the new test T2Candida and blood culture seemed to have the best performance in the detection of invasive candidiasis.
Toenail Onychomycosis: Treatment Options Evaluated
A total of 26 RCTs with 8136 patients were included in this network meta analysis.
Histoplasmosis-Related Healthcare Use, Diagnosis, and Treatment in the US
Histoplasmosis is associated with a wide spectrum of illness and a substantial burden for some patients.
Injection Drug Use May Be an Under-Recognized Risk Factor for Candidemia in Colorado
Approximately 1 in 10 patients with candidemia had a history of recent injection drug use based on a surveillance program in the Denver metropolitan area.
Treatment for Cryptococcosis Gets FDA’s Orphan Drug Designation
The FDA has granted Orphan Drug designation to APX001 (Amplyx Pharmaceuticals) for the treatment of cryptococcosis.
Voriconazole-Resistant Invasive Aspergillosis Associated With Higher Mortality
Patients with voriconazole-resistant invasive aspergillosis have a higher mortality rate compared with patients with voriconazole-susceptible infection.
Isavuconazole Not Noninferior to Caspofungin for Invasive Candida Infections
Isavuconazole did not demonstrate noninferiority compared with caspofungin in the primary treatment of proven candidemia or invasive candidiasis.
Identification and Control of Candida Auris Outbreak in a Hospital ICU
A recent outbreak of Candida auris in an ICU of the Oxford University Hospitals was determined to be primarily linked to reusable temperature probes.
Many Linens Delivered To US Hospitals Contaminated With Mucorales Mold
A recent microbiological surveillance study found that >10% of linens tested positive for the fungi Mucorales at 20% of the hospitals included in the study.
Rezafungin Gets Fast Track, QIDP Status for Prevention of Invasive Fungal Infections
The Phase 3 ReSPECT prophylaxis trial of rezafungin in patients undergoing allogeneic bone marrow transplantation is anticipated to start in the first quarter of 2019.
Coccidioidomycosis Screening Benefits TNFi Therapy Recipients
Screening of asymptomatic coccidioidomycosis within a Coccidioides-endemic area allowed for identifying and managing asymptomatic cases before patients began tumor necrosis factor-α inhibitor therapy.
Novel Nanodiagnostic Panel May Reduce Empiric Antifungal Use in High-Risk Candidemia
A novel nanodiagnostic panel may be helpful in reducing the length of empiric antifungal treatment in patients with multiple risk factors for candidemia.
Want to read more?
Please login or register first to view this content.
